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EDITORIAL

It’s Time to Reverse our Thinking: The Reverse Translation
Research Paradigm
Valentina Shakhnovich∗

THINKING IN REVERSE
In the simplest terms, conventional benchtop-to-bedside
therapeutics research starts in the laboratory and ends in a
clinical trial. The process is linear, with a distinct beginning
and end, fraught with many pitfalls, and, as we have learned
from experience, has a high probability of failure.

children with cystic fibrosis. The ongoing odyssey of repurposing statins for kidney protection illustrates the pivotal
role of reverse translation in uncovering mechanisms of
drug action and highlights how real-life clinical observations
direct benchtop research and the next iteration of therapeutic
experiments.
PATIENT-DRIVEN RAPID TRANSLATION

Benchtop-to-Bedside Research Paradigm
laboratory discovery → clinical trial.
In contrast, reverse translation, also called bedside-tobenchtop research, begins with actual, real-life patient experiences in the clinic, or during a clinical trial, and works
backward to uncover the mechanistic basis for these experiences and clinical observations. In the reverse translation
paradigm, research becomes a seamless, continuous, cyclical process, in which each new patient observation stimulates new testable hypotheses that help refine and direct the
next iteration of benchtop therapeutics research, which, in
turn, leads to the next clinical trial and the next human experience (Figure 1).1
The beauty of reverse translation, unlike benchtop-tobedside research, is that there is no such thing as a failed
clinical trial; only expected and unexpected therapeutic outcomes, and the inevitable variability in the observed human
therapeutic response that needs further explanation and
exploration. The reverse translation issue of Clinical and
Translational Science embraces this broad view of reverse
translation, which encompasses a wide range of topics highly
relevant to clinical pharmacology and patient-centered translational therapeutics research.
DRUG REPURPOSING
A classic example of reverse translation is drug repurposing, an opportunity that arises from clinical observations of
a drug exerting a therapeutic effect unrelated to its primary
therapeutic indication. This phenomenon can result from
a drug acting off-target, or as an unforeseen downstream
consequence of a drug acting on-target, as proposed by
McWilliam et al.,2 for the cholesterol lowering, 3-hydroxy3-methylglutaryl coenzyme A reductase inhibitors, rosuvastatin, and its newly discovered renal-protective potential for

Another contemporary example of reverse translation is the
recent quest for expedited Zika virus diagnostics during the
2015–2016 viral outbreak, a state of public health emergency declared by the World Health Organization and the
United States Department of Health and Human Services,
as outlined by Kurani et al.3 In their commentary, the authors
describe how public need pushed forward the development
of diagnostics and therapeutics necessary to combat the
Zika virus, whereas acknowledging the systems in place that
helped facilitate the rapid translation of in vitro diagnostics
(e.g., Emergency Use Authorization from the US Food and
Drug Administration (FDA)) and the lessons learned from this
translational experience during a public health crisis.
TURNING THE TABLES ON THERAPEUTIC FAILURE
Therapeutic failure is one of the most feared outcomes in
research and clinical practice. However, in the context of
reverse translation, therapeutic failure represents an opportunity to identify new therapeutic targets and novel biomarkers of drug response. This change in attitude toward therapeutic failure is embraced by Becker and Funk4 in their
commentary on the active role of reverse translation in
the advancement of therapeutics for the treatment of rare
rheumatologic disorders.
Shifting the focus from therapeutic failures to recent
anticancer successes at the regulatory level, Faucette
et al.5 distills the comprehensive biopharmacologic evidence submitted to the FDA for approval of oncology
new molecular entities to a practical framework intended
to expedite the clinical development and regulatory submission of future oncology drugs. The framework advocates for careful consideration of the benefit-to-risk profile and dose justification of new molecular entities for
the general population, as well as for select patient
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studies, methodologies to real-world data, Robinson et al.7
eloquently explain how the electronic health record, the
bioinformatics engine of today’s busy medical practice, can
be leveraged as a readily accessible, powerful, convenient
tool for the collection of real-world longitudinal pharmacokinetic and pharmacodynamic data to inform drug development, personalization, and repurposing. Expect more to
come from this emerging reverse translation discipline of
electronic health record/real-world data-informed therapeutics research in the near future.
In summary, Nobel Prize laureate, Sydney Brenner, provides the best contextualization for reverse translation: “we
don’t have to look for model organisms anymore, because
we are the model organism.”1 The reverse translation issue
of Clinical and Translational Science honors this ode to Homo
sapiens.

Conflict of Interest. The author declared no conflicts of interest.
Figure 1 Reverse translation research paradigm. Republished with permission from Wagner, J.A. Patient-centered
reverse translation. Clin. Pharmacol. Ther. (2017). https://doi.
org/10.1002/cpt.902.

subpopulations based on age, race, organ function, genotype and concomitant medication use, recognizing the
importance of real-world interindividual variability to drug
response.
In addition to successfully integrating regulatory science,
reverse translation also encompasses quantitative systems
biology, as explained by Edginton6 in her commentary on the
successful application of physiologically based pharmacokinetic models to inform variability in drug response, including
adverse events and potentially fatal toxicities.
EMBRACING VARIABILITY IN DRUG RESPONSE
Dissecting the origins of the inherent variability in the human
drug response is the cornerstone of reverse translation.
Thus, it comes as no surprise that genome-wide and
phenome-wide association studies fall under the umbrella
term “reverse translation.” In their timely review of the
application of genome-wide and phenome-wide association
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